ARDS

Incannex Healthcare Inc. Quarterly Update, Q1 2024

Retrieved on: 
Tuesday, April 16, 2024
FDA, Psilocybin, Pregabalin, Risk, Obstruction, Phase II, IND, NCT, GAD, Serotonin, Biomarker, Sleep, Deficit spending, Inflammation, Benzodiazepine, Pharmacokinetics, Food, HCQ, IRB, Psychotherapy, Diazepam, Quality of life, OSA, Food and Drug Administration, Pain, Patient, Somnolence, Institutional review board, Safety, Tissue, Bronchitis, PRO, Research, Monash University, Joint, Fatigue, EMA, Dronabinol, PAP, Clinical trial, Asthma, AHI, Accident, COPD, Acetazolamide, NDA, Rheumatoid arthritis, Colitis, Joint stiffness, Obstructive sleep apnea, CBD, Disease, Inflammatory bowel disease, Sleep apnea, Hydroxychloroquine, Cannabidiol, Pharmaceutical industry

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.
  • Incannex is undertaking various U.S. Food and Drug Administration (‘FDA’) research and development (‘R&D’) programs for cannabinoid pharmaceutical products and psychedelic medicine therapies.
  • During the quarter, Incannex released top line results from the PsiGAD1 clinical trial conducted at Monash University, based in Melbourne, Australia.
  • This announcement has been approved for release to NASDAQ by the Incannex Board of Directors.

Boston Medical Center Study Furthers Understanding of Lung Regeneration

Retrieved on: 
Monday, April 22, 2024
Mortality, Boston Medical Center, BMC, Cell Stem Cell, Cell, Chronic obstructive pulmonary disease, Boston University, Transplant, Regenerative medicine, Health, Bacteria, Respiratory disease, MD, Doctor of Philosophy, Disease, Respiratory system, Engineering, Acute respiratory distress syndrome, Pulmonary fibrosis, AT1, Science, Medicine, Knowledge, Infection, COPD, Vaccine

BOSTON, April 22, 2024 /PRNewswire/ -- Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs).

Key Points: 
  • BOSTON, April 22, 2024 /PRNewswire/ -- Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs).
  • As science and medicine have progressed, researchers have identified a clear need for additional knowledge about lung cells to help improve patient health.
  • "Uncovering the ability to generate human alveolar epithelial type I cells (AT1s), and similar cell types, from pluripotent stem cells (iPSCs), has expanded our knowledge of biological processes and can significantly improve disease understanding and management," said Darrell Kotton, MD, Director, Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center.
  • This new study also furthers the CReM's goal of generating every human lung cell type from iPSCs as a pathway to improving disease management and provides a source of cells for future transplantation to regenerate damaged lung tissues in vivo.

Orphan designation: Plerixafor Treatment of acute respiratory distress syndrome (ARDS), 19/02/2024 Positive

Retrieved on: 
Thursday, April 18, 2024
Patient, Committee, Acute respiratory distress syndrome, EMA, IRIS, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of acute respiratory distress syndrome on 19 February 2024.
  • Orphan designation does not mean the medicine is available or authorised for use.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

MiNK Reports Fourth Quarter and Year-End 2023 Results

Retrieved on: 
Thursday, March 21, 2024
Pneumonia, Survival, Survival rate, NSCLC, Disease, Mink, Webcast, Patient, VV, Research, Gene, Cancer, Lung cancer, White lung, IND, Immunity, Society, Therapy, Paclitaxel, TCR, Cell, FDA, Nature Communications, Pharmaceutical industry

MiNK executives will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • “In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity,” said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK.
  • The study reports survival rates exceeding 70% among patients on mechanical ventilation and surpassing 80% among those receiving VV ECMO support.
  • These results stand in stark contrast to the 10% survival rate observed in the in-hospital control during the same period.

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

Retrieved on: 
Monday, March 18, 2024
CCL7, COVID, Major, BMJ Open, IL-6, AKI, Inflammation, Lung, Biomarker, Hospital, Acute respiratory distress syndrome, TMX Group, CXCL10, Acute kidney injury, SARS-CoV-2, Human, TSX, Chemokine, Arch, Cytokine, Periodic breathing, Phase, OTCQB, CXCL8, Liver, Somayaji, BMJ, Randomness, Pharmaceutical industry

New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.

Key Points: 
  • New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.
  • Arch is currently performing a Phase II human trial to support LSALT peptide as a first ever treatment for preventing cardiac surgery-associated acute kidney injury.
  • The results of the Phase II trial provided first-ever evidence validating DPEP-1 as a mediator of organ inflammation and therapeutic target in humans.
  • The new data provides more scientific rationale for Arch to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications, including a larger Phase II trial targeting cardiac surgery-associated AKI, which recently began recruiting patients.

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Retrieved on: 
Tuesday, March 12, 2024
Research, Internal medicine, Overweight, Weill Cornell Medicine, The Obesity Society, Facial muscles, Obesity, Weight loss, SARM, Enobosarm, Education, Flyte, Metabolism, Patient, Weight, Pfizer, Obesity medicine, Davidoff, MD, Weill Cornell Medical Center, Jacobi Medical Center, Eli Lilly and Company, Bangladesh Technical Education Board, MOVE, Boehringer Ingelheim, Directory, Pharmaceutical industry

He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.

Key Points: 
  • He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.
  • Weight loss through any modality produces muscle loss, and there is an unmet need to minimize that in certain groups of patients in order to produce better quality weight loss.
  • In conjunction with a GLP-1 drug, enobosarm has the potential to deliver better quality weight loss while utilizing lower doses of the GLP-1 drug.
  • We are fortunate that Dr. Aronne and the other senior expert members of our Scientific Advisory Board will help guide the enobosarm development program.”

Global Ventilators Market Focused Insights and Outlook 2024-2029 - KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic & GE Healthcare Lead the Market - ResearchAndMarkets.com

Retrieved on: 
Monday, March 18, 2024
Managed Care, General Health, Oncology, Medical Devices, Infectious Diseases, Hospitals, Health Technology, Surgery, Biotechnology, Nursing, Medical Supplies, Practice Management, Health, Growth, Prevalence, Application, Molecular Modeling Database, Incidence, Patient, Ventilation, Hospital, Acute respiratory distress syndrome, GE HealthCare, Asthma, Medtronic, COPD, Nursing care plan, ICU, USD, Ageing, Medical device

The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.

Key Points: 
  • The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.
  • The global ventilators market is one of the fastest-growing segments in the medical devices market.
  • The changing healthcare services in emerging markets and significant achieved development with developed countries consistently drive the ventilator market growth.
  • KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic plc, & GE Healthcare are some leading players currently dominating the global ventilators market.

EQS-News: AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board

Retrieved on: 
Wednesday, March 13, 2024
Bronchiectasis, American Journal, Pulmonology, Asthma, AAT, European Respiratory Society, FERS, GOLD, Patient, Chronic obstructive pulmonary disease, Global Initiative, German Respiratory Society, Critical Care Medicine (journal), COPD, Pharmaceutical industry

AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board

Key Points: 
  • AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board
    The issuer is solely responsible for the content of this announcement.
  • AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board
    Leading pulmonology expert contributes profound clinical experience in inflammatory lung diseases such as bronchiectasis, COPD, asthma, and ARDS to AATec Medical.
  • Munich, Germany – 29.02.2024 – AATec Medical GmbH (AATec), a biotech company developing a multi-product platform technology based on recombinant alpha-1 antitrypsin (AAT), today announced the appointment of Prof. Dr. Claus Franz Vogelmeier, Professor of Medicine and Head of the Department of Pulmonary Medicine at Philipps-University in Marburg, Germany to its Scientific Advisory Board.
  • Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, commented: “We are very pleased to welcome Professor Vogelmeier to our Scientific Advisory Board.

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Retrieved on: 
Wednesday, February 28, 2024
Listing, Calendar, Form, Security (finance), Hand, Research, Cryptocurrency

Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”).

Key Points: 
  • Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”).
  • The Notice states that the Company has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rules.
  • If Nasdaq does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel.
  • The Company continues to work diligently to complete the Form 10-Q and plans to file the Form 10-Q as promptly as possible to regain compliance with the Listing Rule.

BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

Retrieved on: 
Tuesday, February 27, 2024
Human services, Oxygen, Gelsolin, Incidence, Sepsis, ICU, Inflammation, Randomness, Safety, Quality of life, Șaeș, Causality, Drive, Administration, Infection, Nursing care plan, Therapy, Patient, Standard of care, Trauma, Efficacy, Mortality, Plasma, Pharmaceutical industry

Approximately 80 sites in the US, Canada, UK and the EU, including Belgium, France, Italy, Germany, Netherlands, Spain and others will conduct the study.

Key Points: 
  • Approximately 80 sites in the US, Canada, UK and the EU, including Belgium, France, Italy, Germany, Netherlands, Spain and others will conduct the study.
  • The planned primary outcomes are all-cause mortality at Day 28 between treatment groups and incidence, causality, and severity of SAEs in rhu-pGSN vs placebo treatment.
  • Breathing becomes difficult and patients require oxygen, mechanical ventilation and extensive critical care resources, placing a significant burden on the healthcare system.
  • In the U.S. alone, ARDS affects over 700,000 patients per year or roughly 10% of all ICU admissions.